Barclays Maintains Overweight on Celestica, Lowers Price Target to $406

Benzinga Newsdesk www.benzinga.com Negative 89.1%

Neg 89.1% Neu 0% Pos 0%

Barclays analyst Tim Long maintains Celestica (NYSE:CLS) with a Overweight and lowers the price target from $430 to $406.